Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925056 | 0.88 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL4917117 | 0.83 | P2RX7 (1.00) | P2RX7L3MBTL1ALDH1A1RAB9AMAPT | |
| SCHEMBL4916876 | 0.83 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL4918236 | 0.76 | P2RX7 (0.36) | P2RX7 | |
| SCHEMBL4929353 | 0.76 | P2RX7 (0.36) | P2RX7 | |
| SCHEMBL5128960 | 0.73 | P2RX7 (0.53) | P2RX7RAB9AMCHR1 | |
| SCHEMBL5122909 | 0.72 | P2RX7 (0.59) | P2RX7L3MBTL1RAB9ANPC1 | |
| SCHEMBL5123901 | 0.71 | P2RX7 (0.47) | P2RX7MCHR1 | |
| SCHEMBL5128962 | 0.71 | P2RX7 (0.47) | P2RX7MCHR1 | |
| SCHEMBL5122915 | 0.70 | P2RX7 (0.53) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058309-A1 | Novel Compounds 171 | ASTRAZENECA AB | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058309-A1 | Novel Compounds 171 | C1R, F12, ADRA1D | P2RX7 309/4885L3MBTL1 4584/4885ALDH1A1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.